Surrey Heartlands

Joint Formulary & PAD

Darifenacin hydrobromide - Overactive bladder (adults)

You are here : Home > Formulary Search > Darifenacin hydrobromide - Overactive bladder (adults)

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Non Formulary
Formulations :
  • Not Specified
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
NFD1
Restrictions / Comments :

The APC recommend switching darifenacin to solifenacin in appropriate patients.

Documentation

Guidelines (Local)
Selection tool for OAB treatments - Nov 2024
Patient resource
Leaflet-for-trial-of-stopping-OAB-drugs - anticholinergics - Mar 24
Webpage
NICE NG123 Urinary-incontinence-and-pelvic-organ-prolapse-in-women
Webpage
NICE Clinical guideline [CG97] : Lower urinary tract symptoms in men: management
Webpage
LUTS in Men - Management of Overactive Bladder - CKS guidance
Webpage
Urinary incontinence in women - CKS guidelines

PAD Profile

ChemicalSubstance :
Darifenacin hydrobromide
Indication :
Overactive bladder (adults)
Group Name :
Keywords :
OAB, urinary frequency, urge incontinence, LUTS, lower urinary tract symptoms, urinary incontinence, anticholinergics, antimuscarinics
Brand Names Include :
Emselex
Important Information :
Switch to solifenacin recommended (if appropriate)
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Overactive bladder (adults)
Supporting Documents :
6

Other Indications

Below are listed other indications that Darifenacin hydrobromide is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Overactive bladder (adults).

Committee Recommendations (2)

06 Mar 24 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The APC supports patients in trialling a treatment break of their overactive bladder medicines.

A "Leaflet for trial of stopping anticholinergics" can be found in the documents section.

05 Jul 23 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

Darifenacin is non-formulary.

The APC agreed that darifenacin could be switched to solifenacin or an alternative formulary treatment option if solifenacin is contraindicated:

  • In patients with reduced renal function
  • Patients with CNS adverse effects (confusion, drowsiness, halucinations) 
  • Where there is the potential of interactions at Cytochrome P450 3A4
  • in patients where anticholinergics are contraindicated
  • In patients that require a more potent treatment

See Selection Tool for locally agreed OAB treatments.